BNP Paribas Financial Markets grew its position in Accuray Incorporated (NASDAQ:ARAY – Free Report) by 1,650.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 146,384 shares of the medical equipment provider’s stock after purchasing an additional 138,022 shares during the period. BNP Paribas Financial Markets’ holdings in Accuray were worth $263,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in shares of Accuray by 0.3% during the second quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock valued at $5,118,000 after buying an additional 7,500 shares during the period. Foundry Partners LLC lifted its stake in shares of Accuray by 51.3% during the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock worth $3,937,000 after acquiring an additional 741,900 shares during the last quarter. FMR LLC boosted its holdings in Accuray by 27.2% during the 3rd quarter. FMR LLC now owns 582,591 shares of the medical equipment provider’s stock valued at $1,049,000 after acquiring an additional 124,459 shares during the period. Armistice Capital LLC bought a new position in Accuray in the 2nd quarter valued at $910,000. Finally, Bank of New York Mellon Corp increased its stake in Accuray by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 279,426 shares of the medical equipment provider’s stock worth $509,000 after purchasing an additional 8,864 shares during the period. 64.08% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Separately, StockNews.com lowered shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.
Accuray Price Performance
Shares of ARAY stock opened at $1.95 on Tuesday. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. The stock has a fifty day simple moving average of $1.91 and a two-hundred day simple moving average of $1.88. The stock has a market capitalization of $196.10 million, a price-to-earnings ratio of -11.47 and a beta of 1.44. Accuray Incorporated has a twelve month low of $1.40 and a twelve month high of $3.05.
Accuray (NASDAQ:ARAY – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). The company had revenue of $101.55 million during the quarter, compared to the consensus estimate of $98.10 million. Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. During the same quarter in the previous year, the firm posted ($0.03) earnings per share. On average, analysts predict that Accuray Incorporated will post 0.01 EPS for the current fiscal year.
About Accuray
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Further Reading
- Five stocks we like better than Accuray
- What Are the FAANG Stocks and Are They Good Investments?
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- How to Buy Cheap Stocks Step by Step
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- Expert Stock Trading Psychology Tips
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY – Free Report).
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.